Clinical AI has moved past the pilot: the proof is ROI and who watches the errors

Guidance moves inside the tool

The American College of Physicians and OpenEvidence have entered a collaboration to integrate ACP content into the OpenEvidence platform, with OpenEvidence licensing ACP's evidence-based clinical guidance and content from the Annals of Internal Medicine. The aim, as the announcement describes it, is to give internal medicine specialists evidence-based recommendations directly at the point of care. The scale is notable: the ACP has 163,000 members located in more than 172 countries, and internal medicine is the largest specialty on the OpenEvidence platform. OpenEvidence says it is the most popular AI for doctors in the United States and that it is free for all verified US clinicians. m:…0185

Imaging: the numbers are about capacity, not speed alone

AIRS Medical reports on three imaging networks that deployed its SwiftMR AI, and the results it describes are about capacity and capital, not just faster scans. SimonMed Imaging deployed SwiftMR across more than 200 MRI scanners in 10 days, spanning multiple manufacturers, field strengths, and scanner generations. MedStar Health ran a 60-day radiologist-led clinical evaluation and achieved a 38 to 39% total scan-time reduction on Siemens Aera 1.5T protocols, deploying across 13 imaging locations. Invision Sally Jobe increased patient throughput by 29% across three locations within three months, with a 43% average scan-time reduction at its Southwest and Littleton facilities, and avoided more than 1.5 million dollars in capital spending by not purchasing a new scanner. m:…0461

AIRS Medical draws a careful line that buyers should keep in mind. It says successful MRI AI adoption requires clinical validation and enterprise IT readiness to be addressed together, and that quantitative measurements require separate clinical and technical validation beyond reconstruction. Faster scans, it says, only create value if the solution can be trusted, integrated, and used consistently. The point is that a scan-time reduction is a technical result; throughput, avoided capital spending, and consistent use are the business results, and they need different evidence. m:…0461

Pharmacy: audits go from sample to everything

Plenful describes a similar shift in pharmacy work, from sampling to full coverage. Prisma Health previously ran a manual spot audit process for its 340B contract pharmacy relationships that covered only 10% of claims. With Plenful, the company says it now audits 100% of its pharmacy claims, about 80,000 claims in the last fiscal year, and 95% of those claims required no further review. Plenful also says its 340B Missed Opportunities solution identified claims with potential for additional 340B savings, and that Plenful paid for itself within the first year at Prisma Health. m:…2989

At Baptist Health South Florida, the company says pharmacy leaders reduced infusion patient intake delays that had run two to three weeks, and that pharmacy owns the infusion strategy from authorization to denials. The people quoted in the piece frame the work as organizational, not technical. Madeline Camejo views AI as a patient experience and workforce strategy and describes adoption as a trust and change management challenge, advising teams to start with one measurable use case before scaling. Jennifer Bair prioritizes automating repetitive compliance work to return clinician time to patients, and the piece says her auditors shaped the AI implementation and lead its use. That last detail is the one to copy: the people who will be judged on the output helped build it. m:…2989

Who watches the model

Dynatrace's Tom Andriola argues that the other half of this story is oversight, and that healthcare organizations are embedding AI agents into electronic health records, Microsoft 365, Workday, and ServiceNow faster than their governance has caught up. His answer is an Enterprise AI Control Plane, with observability as the foundation: observability supplies the evidence and context that governance depends on, and AI-era observability requires correlating intent, model, infrastructure, and outcome layers in real time. Traditional observability focused on system health, he says, while AI-era observability focuses on decision defensibility. Observability is one of nine capabilities of the control plane he describes. m:…8382

The stakes he names are legal, not just technical. The US Department of Justice prioritizes healthcare fraud enforcement under the False Claims Act, the Department of Health and Human Services proposed updates to the HIPAA Security Rule in December 2024 to strengthen requirements for technology asset inventories and risk analysis, and several states have enacted laws requiring human oversight when AI influences healthcare coverage or care decisions. A wrong answer in the ICU is not a bad search result; it is a decision that may have to be defended to a regulator, a board, or a patient. That is why Andriola frames observability as the evidentiary backbone, not as a dashboard. m:…8382

Translucent AI makes a related point for health system finance. It says AI cuts the time to build a financial scenario from days to minutes, with language models proposing inputs while validated models do the arithmetic, and Monte Carlo runs of 10,000 scenarios combining disruptions to spot early warnings. But it warns the most common failure is false precision: models can write convincing text about financial outcomes with wrong arithmetic. Every parameter needs a source, owner, and approval date in an assumption registry, and parameters calibrated on old claims data may carry forward outdated referral patterns. Speed is the gain; the registry keeps it honest. m:…6629